Detail akcie Genmab online

Business Summary: Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Genmab A/S revenues increased 14% to DKR16.47B. Net income decreased 20% to DKR4.35B. Revenues reflect Denmark segment increase of 10% to DKR16.05B, U.S.A segment increase from DKR0K to DKR380M. Net income was offset by balancing items increase of 42% to DKR5.4B (expense), Foreign exchange rate gain, net decrease from DKR1.03B (income) to DKR0K.